AstraZeneca has agreed to pay Inovio $27.5 million up front and as much as $700 million once the latter's INO-3112 immunotherapy reaches certain developments and commercial milestones.
AstraZeneca To Pay Inovio $727.5 Million For Experimental Cancer Drug
Tech Times - 10 Aug 2015 19:06
AstraZeneca has agreed to pay Inovio $27.5 million up front and as much as $700 million once the latter's INO-3112 immunotherapy reaches certain developments and commercial milestones.
Share this Article
Recommended